Immunovant, Inc.

Biological Products, (No Diagnostic Substances)

IMVT Pharmaceuticals & Biotechnology People in Pharmaceuticals & Biotechnology SEC CIK 0001764013 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$7.72B
206,552,682 shares Covers every share class this company has on file.
Insiders on file
15
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$193.72M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
2.51%
insider-held value divided by market capitalisation

What Immunovant, Inc. reports

Revenue and net income below are for fiscal period FY2026, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
—
No revenue figure: this company’s filings tag profit, but no single revenue total.
Net income
-$505.61M
FY2026 a loss for the period, from this company’s own annual XBRL filings to the SEC
Employees
315
Yahoo Finance
Why the revenue box is blank

US GAAP has no one “total revenue” tag that every filer uses. A bank reports interest and dividend income separately from non-interest income; closed-end funds, blank-cheque companies and some property trusts report the same way; and a company that has not sold anything yet — a drug developer still in trials, for instance — files no revenue at all. Adding two differently defined income lines together would produce a number that appears in no filing, so we publish a revenue figure only where the filing tags one annual, US-dollar revenue fact we can point at. A blank here means no such tag, not that we failed to look.

Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at Immunovant, Inc.

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

Rows are grouped by the role each person reports.

The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.

People who file insider reports against Immunovant, Inc..
Insider Reported role Shares Value Last action
Officers 8
Julia G Butchko Other Executive 440,959 $17.31M S Open-market sale Aug 21, 2024 position reported
Eva Renee Barnett CFO 396,774 $15.57M S Open-market sale Apr 16, 2025 position reported
William L Macias Other Executive 357,353 $14.03M S Open-market sale Feb 19, 2025 position reported
Mark S Levine Other Executive 319,228 $12.53M S Open-market sale Nov 20, 2024 position reported
Michael Geffner Other Executive 217,958 $8.55M S Open-market sale Oct 22, 2025 position reported
Jay S Stout CTO 197,634 $7.76M S Open-market sale Jul 23, 2026 position reported
Melanie Gloria COO 170,273 $6.68M S Open-market sale Aug 20, 2026 position reported
Christopher Van Tuyl General Counsel 147,053 $5.77M S Open-market sale Jul 8, 2026 position reported
Officers who also sit on the board 3
Peter Salzmann CEO 1,178,191 $46.24M S Open-market sale Apr 16, 2025 position reported
Frank Torti Frank Torti President 835,039 $32.78M A Grant or award Apr 7, 2026 position reported
Tiago Girao CFO 208,388 $8.18M S Open-market sale Jul 23, 2026 position reported
Directors 4
George V. Migausky Board Member 137,251 $5.39M A Grant or award Apr 1, 2025 position reported
Atul Pande Board Member 122,851 $4.82M S Open-market sale Aug 28, 2026 position reported
Douglas J Hughes Board Member 120,773 $4.74M A Grant or award Apr 7, 2026 position reported
Andrew J Fromkin Board Member 85,852 $3.37M S Open-market sale May 28, 2026 position reported

Events from filings

Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.

Melanie Gloria sold 14,748 Immunovant, Inc. (IMVT) shares for $563,079 on Jun 26, 2026

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Melanie Gloria sold 14,748 Immunovant, Inc. (IMVT) shares for $563,079 on Jun 26, 2026
Date Insider Transaction Shares Price Value Filing
Jun 26, 2026 Melanie Gloria S Open-market sale 14,748 held after: 227,359 $38.18 $563,079 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Jay S Stout sold 33,277 Immunovant, Inc. (IMVT) shares for $1,270,516 on Jun 26, 2026

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Jay S Stout sold 33,277 Immunovant, Inc. (IMVT) shares for $1,270,516 on Jun 26, 2026
Date Insider Transaction Shares Price Value Filing
Jun 26, 2026 Jay S Stout S Open-market sale 33,277 held after: 218,408 $38.18 $1,270,516 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Andrew J Fromkin sold 210,468 Immunovant, Inc. (IMVT) shares for $7,063,306 on May 28, 2026

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Andrew J Fromkin sold 210,468 Immunovant, Inc. (IMVT) shares for $7,063,306 on May 28, 2026
Date Insider Transaction Shares Price Value Filing
May 28, 2026 Andrew J Fromkin S Open-market sale 210,468 held after: 74,382 $33.56 $7,063,306 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Eric Venker sold 14,229 Immunovant, Inc. (IMVT) shares for $342,854 on Apr 2, 2026

Unusual change in a direct holding

Flagged because the change that day in the shares this person holds directly was unusually large compared with their own earlier changes. The rows below are the open-market trades reported that day; under each share count is the balance the filing reports after that line.

Eric Venker sold 14,229 Immunovant, Inc. (IMVT) shares for $342,854 on Apr 2, 2026
Date Insider Transaction Shares Price Value Filing
Apr 2, 2026 Eric Venker S Open-market sale 12,820 held after: 20,970 $24.04 $308,193 SEC filing ↗
Apr 2, 2026 Eric Venker S Open-market sale 1,409 held after: 19,561 $24.60 $34,661 SEC filing ↗

Total of the rows above: $342,854, in the currency the filings report.

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Recent insider transactions

Of the 204 rows we hold, 0 are open-market purchases and 154 open-market sales (S) — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for Immunovant, Inc., newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Aug 28, 2026 Atul Pande S Open-market sale 1,500 $43.27 $64.9K SEC filing ↗
Aug 28, 2026 Atul Pande M Option exercise or conversion 1,500 $8.43 $12.6K SEC filing ↗
Aug 20, 2026 Melanie Gloria S Open-market sale 3,056 $44.16 $135.0K SEC filing ↗
Jul 24, 2026 Atul Pande S Open-market sale 1,500 $39.80 $59.7K SEC filing ↗
Jul 24, 2026 Atul Pande M Option exercise or conversion 1,500 $8.43 $12.6K SEC filing ↗
Jul 23, 2026 Jay S Stout S Open-market sale 2,857 $38.69 $110.5K SEC filing ↗
Jul 23, 2026 Tiago Girao S Open-market sale 6,798 $38.69 $263.0K SEC filing ↗
Jul 8, 2026 Melanie Gloria S Open-market sale 106 $39.99 $4.2K SEC filing ↗
Jul 8, 2026 Melanie Gloria S Open-market sale 1,930 $39.53 $76.3K SEC filing ↗
Jul 8, 2026 Christopher Van Tuyl S Open-market sale 63 $39.99 $2.5K SEC filing ↗
Jul 8, 2026 Christopher Van Tuyl S Open-market sale 1,143 $39.53 $45.2K SEC filing ↗
Jul 8, 2026 Jay S Stout S Open-market sale 77 $39.99 $3.1K SEC filing ↗
Jul 8, 2026 Jay S Stout S Open-market sale 1,399 $39.53 $55.3K SEC filing ↗
Jul 8, 2026 Jay S Stout S Open-market sale 105 $39.99 $4.2K SEC filing ↗
Jul 8, 2026 Jay S Stout S Open-market sale 1,906 $39.53 $75.3K SEC filing ↗
Jul 2, 2026 Eric Venker S Open-market sale 3,092 $38.48 $119.0K SEC filing ↗
Jul 1, 2026 Eric Venker D Disposition to the issuer 86,629 $38.14 $3.30M SEC filing ↗
Jul 1, 2026 Eric Venker M Option exercise or conversion 92,188 $14.46 $1.33M SEC filing ↗
Jun 26, 2026 Melanie Gloria S Open-market sale 2,966 $38.95 $115.5K SEC filing ↗
Jun 26, 2026 Melanie Gloria S Open-market sale 14,748 $38.18 $563.1K SEC filing ↗
Jun 26, 2026 Jay S Stout S Open-market sale 6,723 $38.94 $261.8K SEC filing ↗
Jun 26, 2026 Jay S Stout S Open-market sale 33,277 $38.18 $1.27M SEC filing ↗
Jun 26, 2026 Christopher Van Tuyl S Open-market sale 2,842 $38.96 $110.7K SEC filing ↗
Jun 26, 2026 Christopher Van Tuyl S Open-market sale 14,982 $38.19 $572.2K SEC filing ↗
Jun 26, 2026 Christopher Van Tuyl M Option exercise or conversion 17,824 $15.20 $270.9K SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Corporate ownership links — 1 filer holds a position

Who owns Immunovant, Inc.

Each row is one filer naming this company.

Funds, trusts and other companies file the same ownership forms that executives do. Everything below is taken from those filings, with the position exactly as the filing states it.

Filers holding a position in Immunovant, Inc.

Funds, trusts and companies that disclose an ownership position in Immunovant, Inc..
Owner Reported role Shares Filed
Roivant Sciences Ltd. ROIV Director,TenPercentOwner 113,317,007

See the full ownership map — every entity that files as an owner of a US public company.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from Immunovant, Inc.’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from Immunovant, Inc.’s own SEC filings multiplied by the closing price we hold for the same stock.